Literature DB >> 17094458

Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2.

Michiyuki Hakozaki1, Hiroshi Hojo, Michiko Sato, Takahiro Tajino, Hitoshi Yamada, Shinichi Kikuchi, Masafumi Abe.   

Abstract

BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) is among the most common soft tissue sarcomas in adults. In order to improve its aggressive course or prognosis and establish new therapeutic methods, molecular genetic and biological characterizations of UPS are required.
MATERIALS AND METHODS: A new human UPS cell line (FPS-1) was established from UPS of the upper arm of a 79-year-old man. The cell line has been maintained for over 14 months with more than 60 passages. FPS-1 cells were characterized using molecular biological methods.
RESULTS: FPS-1 cells showed the same morphological and immunophenotypical characteristics as the primary tumor. Cytogenetic and molecular analyses revealed a nonsense mutation in exon 6 of the p53 gene. Epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) were expressed in FPS-1 cells.
CONCLUSION: FPS-1 cells might be useful for investigating biological behavior and developing new molecular targeting antitumor drugs for UPS with EGFR or COX-2 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094458

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  In Vitro Human Cancer Models for Biomedical Applications.

Authors:  Jane Ru Choi; Gül Kozalak; Ighli di Bari; Quratulain Babar; Zahra Niknam; Yousef Rasmi; Kar Wey Yong
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

2.  Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masako Ishiguro; Teruto Isayama; Masatoshi Naito
Journal:  J Exp Clin Cancer Res       Date:  2010-11-24

3.  Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.

Authors:  Marc Becker; Claudine Graf; Marcus Tonak; Markus P Radsak; Tobias Bopp; Robert Bals; Rainer M Bohle; Matthias Theobald; Pol-Maria Rommens; Dirk Proschek; Thomas C Wehler
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

4.  Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal:  Virchows Arch       Date:  2009-11-18       Impact factor: 4.064

5.  Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Authors:  Rosario Gil-Benso; Javier Megías; Teresa San-Miguel; Sandra Pinto; Robert C Callaghan; Concha López-Ginés; Miguel Cerdá-Nicolás
Journal:  Cytotechnology       Date:  2017-07-04       Impact factor: 2.058

6.  Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.

Authors:  Michiyuki Hakozaki; Takahiro Tajino; Shinichi Konno; Shinichi Kikuchi; Hitoshi Yamada; Michiro Yanagisawa; Jun Nishida; Hiroyuki Nagasawa; Takashi Tsuchiya; Akira Ogose; Masafumi Abe; Hiroshi Hojo
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

7.  Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.

Authors:  Hirofumi Bekki; Kenichi Kohashi; Akira Maekawa; Yuichi Yamada; Hidetaka Yamamoto; Katsumi Harimaya; Michiyuki Hakozaki; Kazuki Nabeshima; Yukihide Iwamoto; Yoshinao Oda
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.